Pulmonary Pharmacology & Therapeutics

Papers
(The TQCC of Pulmonary Pharmacology & Therapeutics is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Celebrating the appointment of Mario Cazzola as Honorary Editor of Pulmonary Pharmacology & Therapeutics94
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies37
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study30
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)28
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d27
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients25
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens20
Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation20
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function18
Editorial Board17
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential16
Editorial Board16
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets14
Exploring the role of β2- and β3-adrenergic receptors in cystic fibrosis14
The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study13
FTO regulates the proliferation and apoptosis of pulmonary artery smooth muscle cells through m6A demethylation modification13
Effects of corticosteroids on Covid-19 patients: A systematic review and meta-analysis on clinical outcomes12
Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea12
Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma12
Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis12
Comparing the outcomes of intrapleural fibrinolytic and DNase therapy versus intrapleural fibrinolytic or DNase therapy: A systematic review and meta-analysis12
Impact on beclometasone dipropionate pharmacokinetics when switching to a low global warming potential propellant in a pressurised metered-dose inhaler11
Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials11
Ferroptosis mediates airway epithelial E-cadherin dysfunction in LPS-induced acute lung injury11
Unveiling the protective role of sevoflurane in video-assisted thoracoscopic surgery associated-acute lung injury: Inhibition of ferroptosis11
Triple inhaled therapy in asthma: Beliefs, behaviours and doubts11
Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant11
Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score10
The era of multiple biologics: Is combination and switching an option in the management of severe asthma?10
Editorial Board10
Editorial Board9
The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study9
Editorial Board9
Ensifentrine approval: A milestone in the treatment of COPD9
Nebulized amphotericin B for preventing exacerbations in allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis9
Editorial Board9
The wonders of stem cells therapeutic application towards chronic obstructive pulmonary disease8
Bispecific domain antibody attenuates airway hyperresponsiveness and pulmonary inflammation in ovalbumin-lipopolysaccharide induced asthma model by inhibiting IL-23 and TNF-α8
Remote preconditioning combined with nebulized budesonide alleviate lipopolysaccharide induced acute lung injury via regulating HO-1 and NF-κB in rats8
Protective effects of adipose-derived biogenic nanoparticles on the pulmonary microvascular endothelial barrier in mice with ventilator-induced lung injury via the TRPV4/ROCK1 signalling pathway8
Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics8
Strongyloides venezuelensis-derived venestatin ameliorates asthma pathogenesis by suppressing receptor for advanced glycation end-products-mediated signaling8
Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea8
Corrigendum to “Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients 8
Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality7
Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan7
Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma7
β-sitosterol targets glucocorticoid receptor to reduce airway inflammation and remodeling in allergic asthma7
The efficacy and safety of inhaled antibiotics for pneumonia: A systematic review and meta-analysis7
Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany7
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study7
Repeated doses of captopril induce airway hyperresponsiveness by modulating the TRPV1 receptor in rats7
0.14430403709412